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Abstract
Phosphatidylinositol 3-kinase (PI-3 kinase) has been implicated in the regulation of many cellular processes, including
growth and transformation. We describe the effect of glucocorticoids on cell growth, phosphoinositide formation and PI-3
kinase activity in Rous sarcoma virus-transformed hamster fibroblasts (HET-SR). Using a prolonged dexamethasone
treatment of HET-SR cells we have selected a new glucocorticoid receptor-positive cell subline, HET-SR(h), that was
resistant to growth inhibitory action of dexamethasone and/or non-hormonal drugs (vinblastine, adriamycin) and was
characterized by higher levels of phosphoinositide formation and increased PI-3 kinase activity. Study of the short-term
hormone action has shown that both dexamethasone-sensitive and -resistant sublines responded to hormone by a decrease in
phospholipid turnover rate. At the same time, in both cell lines activation of PI-3 kinase after dexamethasone addition was
revealed. Dexamethasone-dependent activation of PI-3 kinase was more significant and maintained for a longer period in
HET-SR(h) cells than in parent HET-SR cells. Finally, by transfecting p110*, a constitutively active catalytic subunit of PI-3
kinase, into hormone-sensitive HET-SR cells, we have found a marked increase in cell resistance to growth inhibitory
dexamethasone action. These results suggest that PI-3 kinase may serve as one of the factors providing cell resistance to
cytostatic drugs. ß 1999 Elsevier Science B.V. All rights reserved.
1. Introduction
It has been known for many years that the ability
of steroid hormones to regulate cellular proliferation
is well documented, although the mechanism of cell
response to hormones is poorly understood. The
presence of steroid receptors in cancer cells is an
essential, but not always su⁄cient indicator of cell
sensitivity to hormones [1,2]. Recently it was found
that peptide growth factors play an important role in
cellular response to hormones and act by auto- and/
or paracrine mechanisms interacting with steroids
and mediating their signals. The ability of some re-
ceptor-positive tumor cells to overcome the regula-
tory action of hormones can result from defects in
post-hormone-binding stages of signal transduction
and/or activation of endogenous enzyme systems re-
sponsible for cell growth and survival [3,4].
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It was demonstrated that one of the phospholipid-
related enzymes ^ phosphatidylinositol 3-kinase (PI-3
kinase) ^ plays an important role in major cellular
growth and survival events. This enzyme phospho-
rylates the D-3 position of the inositol ring of phos-
phatidylinositol (PI) to produce PI 3-phosphates. PI-
3 kinase has been implicated in the regulation of
di¡erent cellular responses, including cell growth
[5,6], actin reorganization [7] and cell migration [8].
Recently it was shown that PI-3 kinase was involved
in cellular transformation via the catalytic subunit [9]
and in anti-apoptotic signal transduction [10].
In the present study we analyzed the in£uence of
dexamethasone on phosphoinositide formation and
PI-3 kinase activity in the RSV-transformed hamster
¢broblasts. We have found that dexamethasone
treatment of the transformed ¢broblasts for 3 months
results in selection of a dexamethasone-resistant (but
glucocorticoid receptor-positive) cell clone with the
constitutively activated PI-3 kinase. Using cell clones
with di¡erent sensitivity to dexamethasone we have
demonstrated the strong relationship between hor-
monal or chemical drug resistance and high PI-3 kin-
ase activity.
2. Methods
2.1. Cell culture
Embryonic hamster ¢broblast cells transformed in
vitro by Rous sarcoma virus (HET-SR) were kindly
provided by Dr. G.I. Deichman (Cancer Research
Center, Moscow). The cells were cultured in
DMEM/RPMI medium (1:1) supplemented with
7% fetal serum and 50 U/ml gentamicin.
2.2. Evaluation of growth inhibitory dexamethasone
action
Short-term dexamethasone action was evaluated
after a 3 day exposure of HET-SR cells to 1037 M
dexamethasone in the experimental medium. For as-
sessment of prolonged hormone action cells were cul-
tured in the presence of 1037 M dexamethasone for
3 months. Cell growth was evaluated by MTT test.
Brie£y, the cells were washed twice with phosphate-
bu¡ered saline (PBS) and MTT was added to meas-
ure the amount of viable cells. There was a linear
relationship between the MTT assay and cell number
within the range of the experiments.
2.3. Drug resistance
Cells were grown for 7 days in the presence of
vinblastine or adriamycin in a concentration range
from 1 to 1000 Wg/ml. At the end of exposure the
cells were washed twice with PBS and MTT was
added to measure the amount of viable cells.
2.4. Glucocorticoid receptor (GR) content
GR content in the cell cytosols was measured by
competitive radioligand dextran-coated charcoal as-
say. Brie£y, supernatants obtained after centrifuga-
tion (105 000Ug, 30 min, 4‡C) of cell pellets (107^108
cells/determination) disrupted in liquid nitrogen and
resuspended in 1 ml TED bu¡er (10 mM Tris-HCl,
1.5 mM EDTA, 0.5 mM dithiothreitol ; pH 7.4 with
10% (v/v) glycerol) were incubated overnight at 4‡C
with 30 nM of [3H]dexamethasone (Amersham, UK;
48 Ci/mmol) in the presence or absence of 150-excess
of unlabeled dexamethasone. After that, the un-
bound ligand was absorbed and precipitated with a
dextran-coated charcoal suspension (1.25% charcoal,
0.625% dextran), and protein-bound radioactivity
was measured in the supernatant with a scintillation
L-counter (LS-6500, Beckman, USA). The amount of
speci¢cally (receptor) bound radioactivity was calcu-
lated as the di¡erence between the values obtained in
the presence and absence of the unlabeled hormone
and was expressed in fmoles of [3H]dexamethasone
bound per 1 mg of cytosolic protein. Three con¢r-
matory determinations were performed at each point
of cell growth (see Table 1).
2.5. Phosphoinositide formation
To determine the formation of major phosphoino-
sitides [14C]inositol (0.1 mCi/l) was added to the cul-
ture medium and cells were grown at 37‡C for 48 h.
Cells at their subcon£uent stage were scraped o¡,
washed with PBS, resuspended in minimal volume
of PBS, and phospholipids were separated by thin-
layer chromatography (TLC). To measure the syn-
thesis of the speci¢c PI-3 kinase product phospha-
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tidylinositol 3,4,5-trisphosphate (PI 3,4,5-P3), the
cells were sonicated in bu¡er consisting of 20 mM
HEPES pH 7.5, 10 mM MgCl2, 1 mM PMSF, 10 mg/
ml aprotinin, and 10 mg/ml leupeptin. Equal
amounts of sonicated cells were incubated in a reac-
tion mixture containing 10 mM MgCl2, 20 mM ATP,
20 mM HEPES, 5 mCl/l [Q-32P]ATP and 2 mg/ml
phosphatidylinositol 4,5-biphosphate (PI 4,5-P2) as
a substrate at room temperature for 20 min. To
measure phosphatidylinositol turnover sonicated
cells were incubated in the presence of phosphatidyl-
inositol as a substrate. Phospholipids were analyzed
by TLC. High-performance TLC was performed on
Silica gel 60 plates, saturated for 48 h in methanol/
2% potassium oxalate in water/water (40:24:36) and
activated for 30 min at 100‡C prior to use. Labeled
phosphoinositides were analyzed using a modi¢ed
method in which a simultaneous extraction of lipids
was performed on cells that have been immobilized
on the TLC plates. We have previously shown that
this modi¢cation results in a clear separation of
phospholipids and does not di¡er from the separa-
tion of puri¢ed lipids [11]. In this approach, cell
number is normalized prior to their application to
the TLC plates. Equal amounts of each sample
(105 cells/spot) were applied to oxalate-treated TLC
plates and processed in chloroform/methanol/11%
ammonium hydroxide/water (65:35:6:3). The solvent
was run up to 2 cm from the top of the plate, plates
were air dried, ¢xed and autoradiographed to detect
labeled lipids. Phospholipids were located by auto-
radiography or visualized with iodine vapor. The
amounts of [14C]myo-inositol incorporated into phos-
phatidylinositol, lysophosphatidylinositol and phos-
phatidylinositol monophosphate were quanti¢ed by
densitometric scanning of autoradiographs. 32P in-
corporation into phospholipids was quanti¢ed with
the aid of a phosphorimager.
2.6. PI-3 kinase assay in immunoprecipitates
The cells were lysed in bu¡er containing 50 mM
Tris-HCl, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT, 1 mM PMSF, 0.1 mM Na-or-
thovanadate and 1% aprotinin. The lysates were in-
cubated with antibody to p85 subunit of PI-3 kinase
(Sigma) for 12 h and then for 2 h with protein
G-Sepharose (4 mg/ml of lysate). The immunopre-
cipitates were washed with lysis bu¡er, twice with
PBS/1% Nonidet P-40, twice with 0.5 M LiCl/100
mM Tris-HCl, pH 7.6, and twice with 10 mM Tris-
HCl, pH 7.4/100 mM NaCl/1 mM EDTA. The lipid
kinase assay was performed directly in the beads.
Brie£y, the beads were resuspended in the reaction
mixture containing 10 mM MgCl2, 20 mM ATP,
20 mM HEPES and 5 mCi/l [Q-32P]ATP. Lipid kinase
assays were initiated by addition of the mixture of
phosphatidylinositol/phosphatidylinositol 4-mono-
phosphate (sonicated in 10 mM HEPES pH 7.5,
1 mM EDTA, 0.03% NP-40) at a ¢nal concentration
of 0.2 mg/ml. Reaction mixtures were incubated at
room temperature for 20 min and subsequently dot-
ted onto oxalate-treated TLC plates. The samples
were dried and processed in chloroform/methanol/
11% ammonium hydroxide/water (65:35:6:3). Phos-
pholipids were located by autoradiography or visual-
ized with iodine vapor. 32P incorporation into phos-
phatidylinositol mono- and biphosphate was
quanti¢ed with the aid of a phosphorimager (Bio-
Rad).
2.7. Immunodetection
In immunoblotting experiments monoclonal anti-
bodies to the p85 subunit of PI-3 kinase (Sigma)
were used. The cells were lysed in bu¡er containing
50 mM Tris-HCl, pH 7.5, 1% NP-40, 150 mM NaCl,
1 mM EDTA, 1 mM DTT, 1 mM PMSF, 0.1 mM
Na-orthovanadate and 1% aprotinin. Electrophoresis
of samples containing 100 Wg protein was carried out
in 8% polyacrylamide gel and the proteins were
transferred onto nitrocellulose ¢lters. The ¢lters
were hybridized with primary antibodies and the
complexes were developed using ECL reagent (Amer-
sham).
2.8. Transfection of PI-3 kinase construct
PI-3 kinase plasmid constructs were kindly pro-
vided by Dr. L.T. Williams and co-workers. HET-
SR cells were transfected with p110* plasmid con-
taining cDNA of p110* chimeric protein in which
the catalytic p110 subunit of PI-3 kinase was cova-
lently linked to the iSH2 region of the regulatory p85
subunit [12]. Transfection was performed using Fu-
GENE 6 transfection reagent (Boehringer Mann-
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heim, USA). The cells transfected with p110* plas-
mid or empty mammalian expression vector were
grown for 4 days with or without dexamethasone.
The p85 subunit and p110* construct were co-pre-
cipitated with anti-p85 antibodies and PI-3 kinase
assay was performed as described above. Cell growth
was evaluated by MTT test.
2.9. JNK assay
UV irradiation of the cells was performed as de-
scribed in earlier studies [12]. Brie£y, cells were
washed o¡ the medium and placed in pre-calibrated
areas in a tissue culture hood with their lids o¡, for
the time period necessary for UV-C exposure (30 s to
elicit 40 J/m2). The same medium was added back
immediately after irradiation for 30 min before cells
were harvested. JNK assay was carried out using the
GST-Jun fusion proteins [13]. Brie£y, the GST (glu-
tathione S-transferase)-Jun fusion proteins were
bound to glutathione Sepharose beads and incubated
for 15 min at room temperature with the cellular
extract that contained JNK in the presence of kinase
bu¡er (20 mM HEPES, pH 7.6, 1 mM EGTA, 1 mM
dithiothreitol, 2 mM MgCl2, 2 mM MnCl2, 5 mM
NaF, 1 mM NaVO3, 50 mM NaCl). The beads were
pelleted and thoroughly washed with PBST (150 mM
NaCl, 16 mM sodium phosphate, pH 7.5, 1% Triton
X-100, 2 mM EDTA, 0.1% MeOH, 0.2 mM PMSF,
5 mM benzamidine) before they were incubated with
[Q-32P]ATP (50 cpm/fmol) in the presence of kinase
bu¡er. After extensive washing, the phosphorylated
GST-Jun was boiled in SDS sample bu¡er, and the
eluted proteins were run on a 15% SDS-polyacryl-
amide gel. The gel was dried, and phosphorylation
of the Jun substrate was determined by autoradio-
graphy.
2.10. Statistical analysis
Results were expressed as mean values þ standard
errors of the mean (S.D.). Student’s t-test was used
to compare the mean glucocorticoid concentrations
in the cells. A P value 6 0.05 was considered signi¢-
cant.
3. Results
3.1. Dexamethasone action on the growth of
RSV-transformed ¢broblasts. Selection of
a hormone-resistant subline
Dexamethasone treatment of RSV-transformed
hamster ¢broblasts (HET-SR) for 3 days causes a
signi¢cant inhibition of cell growth (Fig. 1). To study
the possible changes of cell response after prolonged
hormone treatment HET-SR cells were cultured in
the presence of 1037 M dexamethasone for 3 months.
We have found that at the end of this period dexa-
methasone-dependent inhibition of cell growth failed.
After 3 months of hormonal treatment the rate of
cell growth had increased and did not di¡er from
the growth rate of control cells cultured without hor-
mone (Fig. 1).
In the next experiments HET-SR cells were cul-
tured for 3 months in the presence of dexamethasone
and for 1^6 months after hormone withdrawal. It
was established that the sensitivity of these cells to
growth inhibitory hormone action was not restored
after cultivation in dexamethasone-free medium
within at least 6 months (Fig. 2).
Fig. 1. In£uence of dexamethasone on the growth of HET-SR
cells. HET-SR cells cultured without dexamethasone (a), pre-
treated with dexamethasone for 3 days (8) or 90 days (F) were
plated into 24-well plates. Cells were grown without dexametha-
sone (a) or with dexamethasone (8,F) for an additional 3 days
and the cell amount was counted in each well using the MTT
test. Data represent mean values for three independent experi-
ments þ S.D.
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Determination of GR content in the cell cytosols
showed a high level of receptors in the hormone-in-
sensitive cells (Table 1).
We indicated this new hormone-resistant cell sub-
line as HET-SR(h). All experiments described below
were performed using parent cells (HET-SR) and
selected hormone-resistant cells (HET-SR(h) cultured
after hormone withdrawal for at least 6 months.
3.2. Sensitivity of hormone-resistant and parent cells
to non-hormonal cytotoxic agents
HET-SR and HET-SR(h) cells were grown for
7 days in the presence of vinblastine or adriamycin
and the amount of viable cells was counted using the
MTT test. As shown in Fig. 3, HET-SR(h) cells are
more resistant to cytotoxic drug action as compared
to parent HET-SR cells. It is necessary to point out
that an increased level of drug resistance of HET-
SR(h) cells was maintained for a long time (more
than 10 months) after dexamethasone withdrawal.
3.3. Phosphoinositide formation in hormone-resistant
and parent cells
Cells were labeled with [14C]myo-inositol for 48 h
and phosphoinositide formation was measured using
thin-layer chromatography. We have found no sig-
ni¢cant di¡erences in the level of PI or lysophospha-
tidylinositol (lysoPI) formation between the HET-
SR(h) and HET-SR cells. At the same time a di¡er-
ent rate of formation of phosphorylated phosphoino-
sitides was revealed. It was shown that dexametha-
sone-resistant HET-SR(h) cells are characterized by a
higher level of synthesis of phosphatidylinositol
Fig. 2. In£uence of 1037 M dexamethasone on the growth of
HET-SR cells pretreated with hormone for 90 days. HET-SR
cells were precultured with dexamethasone for 90 days, then
180 days after hormone withdrawal and 3 days without (E) or
after (8) the second dexamethasone addition. Cell amount was
counted in each well using the MTT test. Data represent mean
values for ¢ve independent experiments þ S.D.
Fig. 3. In£uence of vinblastine and adriamycin on the growth
of HET-SR and HET-SR(h) cells. HET-SR (8) and HET-
SR(h) (E) cells were grown in the presence of various concen-
trations of vinblastine (A) and adriamycin (B). After 5 days of
growth the cell amount was counted in each well using the
MTT test, and cell survival was calculated as the ratio of viable
cell number in drug-treated and control wells. Data represent
mean values for three independent experiments þ S.D.
Table 1
Glucocorticoid receptor (GR) content in dexamethasone-sensi-
tive and -resistant HET-SR cells
Cells GR (fmol/mg)
HET-SR 46.7 þ 7.01
HET-SR(h) (5 days w/o Dex) 299 þ 262
HET-SR(h) (60 days w/o Dex) 127.5 þ 18.03
P(1^2)6 0.001; P(1^3)6 0.01; P(2^3)6 0.01.
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monophosphate (PIP) than hormone-sensitive HET-
SR cells (Fig. 4A). To measure the synthesis of the
speci¢c PI-3 kinase product PI 3,4,5-P3 the sonicated
cells were incubated in the presence of PI 4,5-P2 and
[Q-32P]ATP for 20 min. Labeled PI 3,4,5-P3 was sep-
arated by TLC as described in Section 2. As depicted
in Fig. 4B, the rate of PI 4,5-P2 phosphorylation was
higher in hormone-resistant cells than in the parent
line.
3.4. Activation of PI-3 kinase in hormone-resistant
cells
Cell lysates prepared from hormone-sensitive
HET-SR and hormone-resistant HET-SR(h) cells
were precipitated with antibodies against the p85
subunit of PI-3 kinase, and PI-3 kinase activity was
measured in immunoprecipitates as described in Sec-
tion 2. We have found that dexamethasone-resistant
Fig. 4. Phosphoinositide formation in HET-SR and HET-SR(h) cells. (A) Cells were labeled with [14C]myo-inositol for 48 h and phos-
phoinositide formation was detected using thin-layer chromatography (see Section 2). Data represent mean values for three independ-
ent experiments þ S.D. (B) Cells were sonicated and synthesis of PI 3,4,5-P3 (PIP3) was measured in the presence of [Q-32P]ATP and
PI 4,5-P2 as a substrate. Phospholipids were separated by high-performance thin-layer chromatography. Quanti¢cation revealed a
3-fold increase in PIP3 level in HET-SR(h) cells as compared with HET-SR. Autoradiograph represents one of four similar experi-
ments. PI, phosphatidylinositol ; lysoPI, lysophosphatidylinositol ; PIP, phosphatidylinositol monophosphate; PIP3, phosphatidyl-
inositol trisphosphate.
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cells are characterized by a greater than 2-fold in-
crease in PI-3 kinase activity (Fig. 5).
To further elucidate this observation we monitored
the amount of p85 subunit of PI-3 kinase using the
Western blotting technique. The results have shown a
signi¢cant accumulation of PI-3 kinase in hormone-
resistant cells as compared to hormone-sensitive cells
(Fig. 6).
3.5. Dexamethasone action on phospholipid
metabolism and PI-3 kinase activity in
hormone-resistant and parent cells
Hormone-resistant and -sensitive cells were cul-
tured in the presence of dexamethasone for 5 days,
then the cells were split and grown with or without
Fig. 5. Anti-p85-immunoprecipitated PI-3 kinase activity from
HET-SR (1,2) and HET-SR(h) (3,4) cells. Cell lysates were pre-
cipitated with antibodies to the p85 subunit of PI-3 kinase and
PI-3 kinase assay was performed directly in the beads as de-
scribed in Section 2. 32P-Labeled phospholipids were then sepa-
rated by TLC. PIP, phosphatidylinositol monophosphate; PIP2,
phosphatidylinositol biphosphate. Quanti¢cation of duplicate
measurements revealed a 2,5-fold increase in PIP and PIP2 level
in HET-SR(h) cells as compared with HET-SR. The results
were con¢rmed in three independent experiments.
Fig. 6. Immunodetection of PI-3 kinase by anti-p85 antibodies.
Electrophoresis and immunoblotting in HET-SR (1,2) and
HET-SR(h) (3,4) cells were carried out as described in Section
2. Quanti¢cation of duplicate measurements revealed a 2-fold
increase in PI-3 kinase content in HET-SR(h) cells. The results
were con¢rmed in four independent experiments.
Fig. 7. Dexamethasone in£uence on 32P incorporation into
phosphatidylinositol in HET-SR and HET-SR(h) cells. The cells
were treated with 1037 M dexamethasone for 5 days, then split
and grown with or without hormone for an additional 2 days.
Then the cells were sonicated and 32P incorporation into PI
was measured (see Section 2). The amount of 32P incorporated
into PI in dexamethasone-treated cells is expressed as a percent-
age of that incorporated into the non-treated cells. Data repre-
sent mean values for ¢ve independent experiments þ S.D.
Fig. 8. Dexamethasone in£uence on anti-p85-immunoprecipi-
tated PI-3 kinase activity from HET-SR and HET-SR(h) cells.
HET-SR (1^3) and HET-SR(h) (4^6) cells were cultured with-
out (1,4) or with (2,3,5,6) 1037 M dexamethasone for 5 days,
then split and dexamethasone-treated cells were grown with
(2,5) or without (3,6) hormone for an additional 2 days. Cell ly-
sates were precipitated with antibodies to the p85 subunit of
PI-3 kinase, and PI-3 kinase assay was performed directly in
the beads. 32P-Labeled phospholipids were then separated by
TLC. Data were quanti¢ed from scanned images. Dexametha-
sone treatment of HET-SR and HET-SR(h) cells for 5 days in-
duced PI-3 kinase activity by 130 and 180%, respectively; dexa-
methasone withdrawal resulted in a decrease of the PI-3 kinase
activities to 110 and 170%, respectively. This is one of three
similar experiments.
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hormone for an additional 2 days. To measure the
rate of phosphatidylinositol turnover cells were soni-
cated, incubated in the presence of exogenous phos-
phatidylinositol and [Q-32P]ATP for 20 min, and la-
beled phospholipids were separated by TLC. The
data obtained have shown (Fig. 7) that both cell lines
responded to dexamethasone addition by the de-
crease of phosphatidylinositol turnover. The rate of
phospholipid turnover in both cell lines was restored
in 2 days after hormone withdrawal (Fig. 7). At the
same time dexamethasone addition caused an activa-
tion of PI-3 kinase in the cells. As revealed, dexa-
methasone-dependent activation of PI-3 kinase was
more signi¢cant in hormone-resistant HET-SR(h)
cells in comparison with hormone-sensitive cells.
Moreover, dexamethasone withdrawal caused a de-
crease in PI-3 kinase activity up to the control level
in hormone-sensitive cells while activation of PI-3
kinase in hormone-resistant cells was maintained
after hormone withdrawal (Fig. 8).
3.6. Dexamethasone sensitivity of cells transfected
with PI-3 kinase
To further investigate the role of PI-3 kinase in
hormonal resistance, we transfected parent HET-SR
cells with p110* plasmid constructs containing
cDNA of the constitutively active catalytic subunit
of PI-3 kinase. Transfected cells exhibited a greater
than 4-fold increase in PI-3 kinase activity within a
minimum of 3 days after transfection (Fig. 9A). The
MTT test showed that p110*-transfected cells were
less sensitive to growth inhibitory dexamethasone ac-
tion than control transfectants, which received the
empty mammalian expression vector (Fig. 9B).
3.7. Relationship between PI-3 kinase and
JNK activities
JNK activity in hormone-resistant and -sensitive
cells was monitored before and after UV irradiation.
Fig. 9. E¡ect of p110* transfection on PI-3 kinase activity and
cell sensitivity to dexamethasone. (A) HET-SR cells were trans-
fected with p110* plasmid (p110*) or empty vector (Co). Three
days after transfection anti-p85-immunoprecipitated PI-3 kinase
activity was measured as described in Section 2. The autoradio-
graph represents one of three similar experiments. (B) HET-SR
cells were grown for 4 days after transfection in the presence or
absence of dexamethasone and cell growth was evaluated by
MTT test. Data are expressed as percentage of the respective
control values (100%3number of the cells grown without dexa-
methasone) and are means of three independent experiments.
Fig. 10. UV-induced JNK activation in HET-SR and HET-
SR(h) cells. The cells were exposed to UV (30 s to elicit 40
J/m2), the same medium was added back for 30 min before cells
were harvested. JNK activity in cell lysates was measured as de-
scribed in Section 2 using the GST-Jun fusion proteins. Quanti-
¢cation of the e¡ect of UV exposure on JNK activity in HET-
SR and HET-SR(h) cells revealed an increase in the activity by
430 and 240%, respectively. The data were con¢rmed in three
independent experiments.
BBAMCR 14494 29-6-99
M.A. Krasil’nikov et al. / Biochimica et Biophysica Acta 1450 (1999) 434^443 441
Brie£y, the cells were exposed to UV (30 s to elicit 40
J/m2), the same medium was added back for 30 min
before the cells were harvested. JNK activity in cell
lysates was measured as described [13]. The data
show that the basal level of JNK activity was not
di¡erent in these cells. At the same time monitoring
of JNK in the UV-treated cells showed a reduced
level of JNK activation in the cells with high PI-3
kinase activity in hormone-resistant HET-SR(h) cells
(Fig. 10).
4. Discussion
The role of membrane lipids as second messengers
in growth signaling networks has been well charac-
terized. Growth factor-induced mitogenesis includes
phosphorylation of growth factor receptors, stimula-
tion of membrane phospholipid turnover, a cascade
of kinase reactions, activation of transcriptional fac-
tors etc. Earlier we have shown that steroid hor-
mones which act as proliferation inhibitors (proges-
terone, dexamethasone) prevent the growth factor-
induced activation of phospholipid turnover in hor-
mone-sensitive cells [11,14]. However, the mechanism
of the regulation of cell sensitivity to steroid hor-
mones is still unclear. As revealed, the presence of
speci¢c hormone-binding receptors in cancer cells is
not a su⁄cient indicator of cell sensitivity to hor-
mones and some receptor-positive tumor cells can
overcome growth inhibitory hormone action [1,2].
In the present study using a prolonged dexametha-
sone treatment of RSV-transformed hamster ¢bro-
blasts we have selected a new hormone-resistant
cell subline, HET-SR(h). Ligand-binding studies re-
vealed a high GR level in these cells that even ex-
ceeded the level in parent cells (Table 1). Thus, the
decrease of HET-SR(h) cell sensitivity to dexametha-
sone was not associated with the de¢ciency in GR
content.
Analysis of cell sensitivity to non-hormonal cyto-
toxic agents showed that hormone-resistant HET-
SR(h) cells are characterized by an increased level
of resistance to chemical drugs: vinblastine and
adriamycin (Fig. 3).
To assess the early stages of mitogenic signal
transduction, we measured the rate of phosphoinosi-
tide formation in both cell lines. It was found that
phosphatidylinositol synthesis did not di¡er in HET-
SR(h) and HET-SR cells. At the same time dexa-
methasone-resistant HET-SR(h) cells were character-
ized by a higher level of PIP than hormone-sensitive
HET-SR cells (Fig. 4A). Moreover, analysis of the
formation of the speci¢c PI-3 kinase product PI
3,4,5-P3 in the presence of PI 4,5-P2 as a substrate
showed an increased rate of PI 4,5-P2 phosphoryl-
ation in hormone-resistant cells (Fig. 4B).
To further elucidate this observation we have eval-
uated PI-3 kinase activity in hormone-sensitive and
-resistant cells. As revealed, hormone-resistant cells
exhibited a signi¢cantly increased level of PI-3 kinase
activity associated with an increased amount of PI-3
kinase protein (Figs. 5 and 6). Thus, our data suggest
that prolonged hormonal treatment should increase
the quantity of the active PI-3 kinase in the cells.
The mechanism by which the PI-3 kinase activity
increases in hormone-resistant cells is still unclear. As
mentioned above, hormone-resistant cells were se-
lected after long-term dexamethasone treatment of
the parent HET-SR cells. So, we could propose
that dexamethasone addition to the cells might in-
duce two independent events: inhibition of mitogenic
signal transduction and cell growth, and at the same
time compensatory activation of the enzymes re-
sponding for cell survival, as found for PI-3 kinase.
Consistently with this hypothesis, we have investi-
gated short-term dexamethasone action on the rate
of phosphatidylinositol turnover (that usually corre-
lates with cell growth) and PI-3 kinase activity in
hormone-sensitive and -resistant cells. The results ob-
tained have shown that both cell lines responded to
hormone by a decrease of phospholipid turnover rate
(Fig. 7). In parallel, monitoring of PI-3 kinase activ-
ity revealed the activation of PI-3 kinase in the cells
after dexamethasone addition. Dexamethasone-de-
pendent activation of PI-3 kinase was more signi¢-
cant and maintained for a longer period in hormone-
resistant HET-SR(h) cells than in hormone-sensitive
cells (Fig. 8). To determine the role of PI-3 kinase in
hormonal resistance we transfected dexamethasone-
sensitive HET-SR cells with p110* plasmids contain-
ing cDNA of a constitutively active catalytic subunit
of PI-3 kinase. p110* is a chimeric protein in which
catalytic the p110 subunit is covalently linked to the
iSH2 region of the regulatory p85 subunit of PI-3
kinase [12]. As is known, iSH2 region mediates the
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interaction of p85 with the p110 subunit and this
interaction is required for lipid kinase and protein
kinase activities of PI-3 kinase. Expression of consti-
tutively active p110* protein is su⁄cient to trigger
downstream signaling pathways independently of
growth factor stimulation [15]. Our data have shown
that p110* transfection results in a marked increase
in cell resistance to growth inhibitory dexamethasone
action (Fig. 9).
It was likely that PI-3 kinase belongs to the family
of enzymes compensatory activated after hormonal
inhibition of cell growth and providing the cell with
the ability to overcome the growth inhibitory action.
The latter is in agreement with the studies of other
investigators who demonstrated the important role
of PI-3 kinase in cellular transformation [9] and in
mediating an anti-apoptotic signal [10].
One would also expect that PI-3 kinase might exert
its e¡ects through one of the associated kinases. In
particular, stress activated kinases (jun NH2 terminal
kinases, JNK) are among the enzymes associated
with PI-3 kinase. Proteins implicated in JNK activa-
tion (Grb-2, p21-ras) were shown to interact with PI-
3 kinase [16,17]. PI-3 kinase activities were reported
to be in inverse correlation with JNK [16]. The re-
sults of our experiments demonstrate the reduced
level of UV-dependent JNK activation in the hor-
mone-resistant cells which exhibit higher activity of
PI-3 kinase (Fig. 10). Further studies should deter-
mine the role of possible messengers such as Akt/
PKB in the coordinate regulation of JNK and PI-3
kinase.
In conclusion, we suggest that prolonged hormone
treatment has resulted in the selection of a GR-pos-
itive cell subline which exhibited a high level of PI-3
kinase activity and low sensitivity to hormonal and
non-hormonal cytotoxic drugs, and conclude that PI-
3 kinase may serve as one of the factors providing
the cell survival after cytotoxic/cytostatic drug ac-
tion.
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